-
Article
2024: The year to take European action on diabetes to the next level
-
Article
Open AccessConsensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type...
-
Article
Review Article – Diabetes Technology in the Hospital: An Update
There have been many developments in diabetes technology in recent years, with continuous glucose monitoring (CGM), insulin pump therapy (CSII) and automated insulin delivery (AID) becoming progressively accep...
-
Article
Open AccessGut microbiome shifts in people with type 1 diabetes are associated with glycaemic control: an INNODIA study
The gut microbiome is implicated in the disease process leading to clinical type 1 diabetes, but less is known about potential changes in the gut microbiome after the diagnosis of type 1 diabetes and implicati...
-
Article
How medical schools can prepare students for new technologies
Patient educators and nurses can demonstrate the real-life use of health technologies.
-
Article
Open AccessThe INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults
Type 1 diabetes is an heterogenous condition. Characterising factors explaining differences in an individual’s clinical course and treatment response will have important clinical and research implications. Our...
-
Article
The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study
The aim of this study was to evaluate the association of chronic complications with time in tight range (TITR: 3.9–7.8 mmol/l) and time in range (TIR: 3.9–10.0 mmol/l) in people with type 1 diabetes.
-
Article
Open AccessComparative impact of Roux-en-Y gastric bypass, sleeve gastrectomy or diet alone on beta-cell function in insulin-treated type 2 diabetes patients
Although bariatric surgery is an effective treatment for type 2 diabetes by inducing weight loss and augmenting gut hormone secretion, the immediate effect on beta-cell function itself remains to be elucidated...
-
Article
Cost–utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium
The aim of this study was to assess the long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring (rtCGM) with alert functionality compared with FreeStyle Libre 1 intermittently scanned...
-
Article
Open AccessCVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform f...
-
Article
Type 1 diabetes mellitus: a brave new world
One hundred years after the Nobel prize was bestowed on Banting and McLeod for the ‘discovery’ of insulin, we are again seeing major evolutions in the management of type 1 diabetes mellitus, with the prospect ...
-
Article
Open AccessA first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab
We hypothesised that islet beta cell antigen presentation in the gut along with a tolerising cytokine would lead to antigen-specific tolerance in type 1 diabetes. We evaluated this in a parallel open-label Pha...
-
Article
Open AccessTargeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory
There is a growing need for markers that could help indicate the decline in beta cell function and recognise the need and efficacy of intervention in type 1 diabetes. Measurements of suitably selected serum ma...
-
Article
Open AccessUtility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review
The greatest change in the treatment of people living with type 1 diabetes in the last decade has been the explosion of technology assisting in all aspects of diabetes therapy, from glucose monitoring to insul...
-
Article
Incretins beyond type 2 diabetes
Incretin-based therapies, in particular glucagon-like peptide-1 (GLP-1) receptor agonists, have been evaluated in other forms of diabetes, but randomised controlled trials are mainly limited to people living w...
-
Article
Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine
Precision medicine is part of the logical evolution of contemporary evidence-based medicine that seeks to reduce errors and optimize outcomes when making medical decisions and health recommendations. Diabetes ...
-
Article
Applying the WHO global targets for diabetes mellitus
In 2022, the WHO created the first global targets for diabetes mellitus. The targets are that by 2030, 80% of people living with diabetes mellitus are diagnosed, and that 80% of those living with diabetes mell...
-
Article
Open AccessClosed-loop insulin delivery in pregnant women with type 1 diabetes (CRISTAL): a multicentre randomized controlled trial – study protocol
Despite increasing use of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII, insulin pumps) in type 1 diabetes (T1D) in pregnancy, achieving recommended pregnancy glycaemic...
-
Article
Open AccessCVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10–12, 2022. Following the tradition of previous summits, this reference congr...
-
Article
The changing landscape of scientific communication at EASD
